MarketAnimal vaccination
Company Profile

Animal vaccination

Animal vaccination is the immunisation of a domestic, livestock or wild animal. The practice is connected to veterinary medicine. The first animal vaccine invented was for chicken cholera in 1879 by Louis Pasteur. The production of such vaccines encounter issues in relation to the economic difficulties of individuals, the government and companies. Regulation of animal vaccinations is less compared to the regulations of human vaccinations. Vaccines are categorised into conventional and next generation vaccines. Animal vaccines have been found to be the most cost effective and sustainable methods of controlling infectious veterinary diseases. In 2017, the veterinary vaccine industry was valued at US$7 billion and it is predicted to reach US$9 billion in 2024.

History
Animals have been both the receiver and the source of vaccines. Through laboratory testing, the first animal vaccine created was for chicken cholera in 1879 by Louis Pasteur. Pasteur also invented an anthrax vaccine for sheep and cattle in 1881, and the rabies vaccine in 1884. The infected nerve tissue was dried to weaken the virus. Subsequently, in 1885, the vaccine was given to a 9-year-old boy infected with the rabies disease, Joseph Meister, who survived when no one had before. An indirect view of animal vaccinations is seen through smallpox. This is because the vaccine given to humans was animal based. Smallpox was a deadly disease most known for its rash and high death rate of 30% if contracted. Edward Jenner tested his theory in 1796, that if a human had already been infected with cowpox that they would be protected from smallpox. It proved to be true and thus started the pathway to the eradication of the disease. Through the World Health Organization's (WHO) eradication effort, at least 80% of people were vaccinated in every country. Subsequently, case finding and then ring vaccination was used, resulting in smallpox becoming the first eradication of a disease through vaccination in 1980. == Issues ==
Issues
The main issues in relation to the vaccination of animals is access and availability. Vaccines are the most cost-effective measure in preventing disease in livestock populations, although the logistics of distributing vaccines to marginalised populations is still a challenge. Accessibility Most smallholder farmers' (SHFs) livestock in marginalised populations (MPs) die as a result of a disease, they do not reach their full potential, or they transmit a disease. The root of this issue could be prevented or controlled by increasing the accessibility to animal vaccines. Livestock are necessary to an estimated 600 to 900 million poor farmers in the developing world. This is because the animals provide food, income, financial reserve and status. Availability The diseases have been characterised into diseases that cause economic losses, government-controlled diseases, and neglected diseases, which all link to availability. The economic losses category entails necessary vaccines in developing countries normally produced by the private sector that make little to no profit, these companies require community support to continue producing. Whereas, government-controlled diseases are controlled by government policy, the main issue here is if the vaccine is expensive it therefore becomes less available to poor farmers. Furthermore, there are some animal diseases which have been neglected as they mainly only affect poor communities, and thus will not be profitable. This is because producers target the largest markets first to ensure their return on investment (ROI). For example, the reason why dog transmitted rabies is taking time to eradicate is because it only affects the developing world, thus it is not able to be produced on a large and profitable scale. Other issues Some other issues include but are not limited to: economic barriers, political barriers, technical and scientific barriers, regulatory barriers, field use barriers, and social and perception barriers. == Possible solutions ==
Possible solutions
There are possible solutions in terms of the issues in the sector of animal vaccinations. These include innovations in both the scientific and the regulatory fields. It has been suggested that regulations are converged between regions and all animal vaccines can be standardised with the same RNA or DNA backbone. It has been found that there needs to be a better mutual understanding between regulators, academia and industry. Some other solutions include: free rabies vaccine programs, subsidies as needed, form partnerships across regions (mainly in terms of vaccine banks), a decrease in government taxes, providing positive incentives for disease recording, and building partnerships between global and local manufacturers. == Human health ==
Human health
The production of vaccines for animals and humans has always been linked, this relationship has been coined 'One Health', as at least 61% of all human pathogens originate from animals. Two main examples of this link are the rabies and smallpox vaccines. In many cases vaccinating animals is important not only to the animals' health but also to human health and prosperity. The term zoonotic disease defines a disease that can be transferred from animals to humans. Rabies A current and prominent example of a zoonotic disease is rabies. It is spread from an animal to humans and other animals through saliva, bites and scratches. The vaccine for rabies can be administered prior or post to being infected, as a result of the long incubation period of the disease. == Regulation of animal vaccines compared to human vaccines ==
Regulation of animal vaccines compared to human vaccines
The development of animal vaccines has less regulatory requirements than human vaccines. This has resulted in less time and money involved in the creation and production of animal vaccines. The human vaccine development process generally takes 10 to 15 years, whereas the animal vaccine process only takes an average 5 to 7 years to produce. Albeit, the ability to prioritise potential vaccine targets and the use of studies to test safety is less in the animal vaccine production compared to human vaccines. Prioritisation of potential vaccines Pets has grown at a fast rate over time as owners are concerned for their companion animals' health. BSA can cause severe allergic reactions that can lead to death. ==Vaccine production==
Vaccine production
Conventional vaccines The main conventional vaccines are Live-attenuated and Inactivated. Live-attenuated vaccines use a weakened form of the virus or bacteria that causes the disease. This form of inoculation is the closest to the actual infection, and thus it has been seen to have a stronger effect than the other types of conventional vaccines. Albeit, there have been some safety issues related to live-attenuated vaccines. There is a potential for unintended outcomes if another being other than the target species takes the vaccine, and there have been instances where this type of vaccine creates false positives when animals are tested and therefore rids a country of their disease free status (as has been seen through Foot and Mouth Disease, FMD). == Vaccinating companion animals ==
Vaccinating companion animals
The Vaccinations Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA) have defined the core, non-core and not recommended vaccinations for dogs and cats. Core vaccines protect animals against severe global diseases. Where rabies is endemic the associated vaccine is treated as being in the core category. == See also ==
tickerdossier.comtickerdossier.substack.com